Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Receivables (2020 - 2025)

Bioventus (BVS) has disclosed Receivables for 6 consecutive years, with $131.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Receivables rose 3.07% year-over-year to $131.4 million, compared with a TTM value of $131.4 million through Dec 2025, up 3.07%, and an annual FY2025 reading of $131.4 million, up 3.07% over the prior year.
  • Receivables was $131.4 million for Q4 2025 at Bioventus, up from $130.4 million in the prior quarter.
  • Across five years, Receivables topped out at $158.5 million in Q4 2021 and bottomed at $89.5 million in Q2 2021.
  • Average Receivables over 5 years is $126.8 million, with a median of $128.0 million recorded in 2021.
  • The sharpest move saw Receivables soared 45.36% in 2021, then fell 19.33% in 2023.
  • Year by year, Receivables stood at $128.4 million in 2021, then increased by 6.32% to $136.6 million in 2022, then fell by 9.9% to $123.0 million in 2023, then increased by 3.59% to $127.5 million in 2024, then grew by 3.07% to $131.4 million in 2025.
  • Business Quant data shows Receivables for BVS at $131.4 million in Q4 2025, $130.4 million in Q3 2025, and $135.3 million in Q2 2025.